| dc.description.abstract | Dans ce numéro les articles suivants sont analysés : 1. Blandi L, Bertuccio P, Signorelli C, Brand H, Clemens T, Renzi C, et al. Herpes zoster as risk factor for dementia: a matched cohort study over 20 years in a 10-million population in Italy. J Prev Alzheimers Dis. 2025:100167. 2. Eyting M, Xie M, Michalik F, Hess S, Chung S, Geldsetzer P. A natural experiment on the effect of herpes zoster vaccination on dementia. Nature. 2025;641(8062):438-46. 3. Imamura K, Kawai H, Ejiri M, Sasai H, Ihara K, Nakada H, et al. Association between the use of information and communication technology and cognitive decline stratified by social isolation: The Otassha study. J Prev Alzheimers Dis. 2025:100138. 4. Moses Appel A, Jensen-Dahm C, Munk Laursen T, Waldemar G, Janbek J. The Effect of Influenza Vaccination on Hospitalization and Mortality Among People With Dementia. J Am Geriatr Soc. 2025;73(5):1498-505. 5. Myran DT, Pugliese M, Harrison LD, Stall NM, Webber C. Risk of Dementia in Individuals With Emergency Department Visits or Hospitalizations Due to Cannabis. JAMA Neurol. 2025;82(6):570-9. 6. Oh HS, Urey DY, Karlsson L, Zhu Z, Shen Y, Farinas A, et al. A cerebrospinal fluid synaptic protein biomarker for prediction of cognitive resilience versus decline in Alzheimer's disease. Nat Med. 2025;31(5):1592-603. 7. Pansieri J, Pisa M, Yee S, Gutnikova A, Ridgeon E, Hickman R, et al. Neuropathological Evidence of Reduced Amyloid Beta and Neurofibrillary Tangles in Multiple Sclerosis Cortex. Ann Neurol. 2025(6):1067-73. 8. Pomirchy M, Bommer C, Pradella F, Michalik F, Peters R, Geldsetzer P. Herpes Zoster Vaccination and Dementia Occurrence. JAMA. 2025;333(23):2083-92. 9. Wang Y, Zang EX, Davis-Plourde K, Vander Wyk B, Gill TM, Becher RD. Incidence of Frailty, Dementia, and Disability Among Community-Living Older Americans According to County-Level Disadvantage. J Am Geriatr Soc. 2025(6):1847-56. 10. Zimmer JA, Ardayfio P, Wang H, Khanna R, Evans CD, Lu M, et al. Amyloid-Related Imaging Abnormalities With Donanemab in Early Symptomatic Alzheimer Disease: Secondary Analysis of the TRAILBLAZER-ALZ and ALZ 2 Randomized Clinical Trials. JAMA Neurol. 2025;82(5):461-9. | |
